PPA
RNAC icon

Parametric Portfolio Associates’s Cartesian Therapeutics RNAC Stock Holding History

Parametric Portfolio Associates’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$23K Buy
+634
New +$39.7K ﹤0.01% 3658
2021
Q4 		– Sell
-619
Closed -$77K – 3689
2021
Q3 		$77K Buy
+619
New +$74.7K ﹤0.01% 3554
2019
Q2 		– Sell
-341
Closed -$24K – 3997
2019
Q1 		$24K Buy
+341
New +$21.6K ﹤0.01% 3909

Other funds holding RNAC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parametric Portfolio Associates's RNAC Position: Q1 2022 in Review

Parametric Portfolio Associates opened a new position in Cartesian Therapeutics (RNAC) in Q1 2022: 634 shares worth $23K. The stake represents ﹤0.01% of the portfolio and ranks #3658 among its holdings. This is a return to the name: Parametric Portfolio Associates previously reported a position in RNAC as recently as Q3 2021.

Parametric Portfolio Associates first reported a position in RNAC in Q1 2019 and has held it in 3 quarters since. The position peaked at $77K in Q3 2021. 102 funds tracked by Wall St. Rank hold RNAC as of Q1 2022.

  • Parametric Portfolio Associates held 634 shares of Cartesian Therapeutics worth $23K as of Q1 2022.
  • Cartesian Therapeutics was a new Parametric Portfolio Associates position in Q1 2022.
  • Cartesian Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3658 holding.
  • Parametric Portfolio Associates first reported a position in Cartesian Therapeutics in Q1 2019 and has held it in 3 quarters since.
  • Parametric Portfolio Associates's Cartesian Therapeutics position peaked at $77K in Q3 2021.
  • 102 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.